Medi-first Sinus Decongestant
Loading...Medi-first Sinus Decongestant Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
NOT FOR INJECTION.
Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones, including ofloxacin. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin. If an allergic reaction to ofloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management, including intubation should be administered as clinically indicated.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:
| CONJUNCTIVITIS: |
|
| Gram-positive bacteria: |
Gram-negative bacteria: |
| Staphylococcus aureus |
Enterobacter cloacae |
| Staphylococcus epidermidis |
Haemophilus influenzae |
| Streptococcus pneumoniae |
Proteus mirabilis |
| |
Pseudomonas aeruginosa |
| CORNEAL ULCERS: |
|
| Gram-positive bacteria: |
Gram-negative bacteria: |
| Staphylococcus aureus |
Pseudomonas aeruginosa |
| Staphylococcus epidermidis |
Serratia marcescens* |
| Streptococcus pneumoniae |
Anaerobic species: |
| |
Propionibacterium acnes |
* Efficacy for this organism was studied in fewer than 10 infections
History
There is currently no drug history available for this drug.
Other Information
Ofloxacin ophthalmic solution 0.3% is a sterile ophthalmic solution. It is a fluorinated carboxyquinolone anti-infective for topical ophthalmic use.
Chemical Name: (±)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H pyrido [1,2,3-de]-1,4 benzoxazine-6-carboxylic acid.
Contains: Active: ofloxacin 0.3% (3 mg/mL)
Preservative: benzalkonium chloride (0.005%)
Inactives: sodium chloride and water for injection. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH.
Ofloxacin ophthalmic solution is unbuffered and formulated with a pH of 6.4 (range 6.0 to 6.8). It has an osmolality of 300 mOsm/kg. Ofloxacin is a fluorinated 4-quinolone which differs from other fluorinated 4-quinolones in that there is a six member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure.
Image
Sources
Medi-first Sinus Decongestant Manufacturers
-
Unifirst First Aid Corporation
![Medi-first Sinus Decongestant (Phenylephrine Hydrochloride) Tablet, Film Coated [Unifirst First Aid Corporation]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Medi-first Sinus Decongestant | Fdc Limited
The recommended dosage regimen for the treatment of bacterial conjunctivitis is:
Days 1 and 2
Instill one to two drops every two to four hours in the affected eye(s).
Days 3 through 7
Instill one to two drops four times daily.
The recommended dosage regimen for the treatment of bacterial corneal ulcer is:
Days 1 and 2
Instill one to two drops into the affected eye every 30 minutes, while awake. Awaken at approximately four and six hours after retiring and instill one to two drops.
Days 3 through 7 to 9
Instill one to two drops hourly, while awake.
Days 7 to 9 throughtreatment completion
Instill one to two drops, four times daily.
-
Unifirst First Aid Corporation
Medi-first Sinus Decongestant | L. Perrigo Company
• take only as directed – see Overdose warning • use dose cup • do not exceed 4 doses per 24 hrsadults & children 12 yrs & over
30 mL (2 TBSP) every 6 hrs
children 4 to under 12 yrs
ask a doctor
children under 4 yrs
do not use
![Medi-first Sinus Decongestant (Phenylephrine Hydrochloride) Tablet, Coated [Unifirst First Aid Corporation]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f90bd64a-dd1a-4319-87cd-427d57f677ab&name=b9b6f9b4-5f5d-4b07-9cca-40e13636b2a2-01.jpg)
Login To Your Free Account